ArticleKidney international reports2025
Urinary Dickkopf-3 Predicts GFR Loss in the General Population.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transition from acute kidney injury to chronic kidney disease: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic kidney disease (CKD) affects > 800 million people globally, with prevalence expected to increase, emphasizing the need for effective early detection and management strategies. Urinary Dickkopf-3 (uDKK3), a profibrotic glycoprotein from renal tubular cells, has been linked to acute kidney injury (AKI) and CKD progression. This study assesses uDKK3 as a biomarker for predicting glomerular filtration rate (GFR) decline in the general population. Methods: We conducted a prospective cohort study with 1316 participants aged 55 to 69 years from the Renal Iohexol Clearance Survey (RENIS) (2014-2015), undergoing 1 to 3 GFR measurements using iohexol clearance over 5.3 years. uDKK3 levels were normalized to creatinine (Cr), categorizing participants by uDKK3/Cr levels: undetectable, low (detectable < 400 pg/mg), and high (≥ 400 pg/mg). Linear mixed models were used to evaluate the relationship between uDKK3/Cr levels and GFR decline rate. Logistic regression was used to examine the association between uDKK3/Cr groups and accelerated GFR decline, defined as the top 10% steepest declines. Results: The mean annual GFR decline rate was -1.33 ml/min per 1.73 m Conclusion: Elevated uDKK3 levels were linked to steeper GFR decline, independent of conventional CKD risk factors, confirming uDKK3 as a promising biomarker for early identification of individuals at risk for rapid GFR loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.